SIGA Technologies, Inc., a commercial-stage pharmaceutical company focusing on the health security market, announced on January 13 that the Public Health Agency of Canada has awarded a contract to Meridian Medical Technologies, Inc. for the purchase up to approximately $33 million of oral TPOXX® (tecovirimat) within five years. Since 2019, SIGA has an international promotion agreement with Meridian, under which, Meridian will promote the sale of oral TPOXX for the treatment of smallpox in all international markets, except the United States.
Read more about this news here.
